SIGNIFY N.V. EO -,01/ NL0011821392 /
6/21/2025 1:04:27 PM | Chg. 0.000 | Volume | Bid1:04:27 PM | Ask1:04:27 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
22.040EUR | 0.00% | - Turnover: - |
22.040Bid Size: - | 22.100Ask Size: - | 2.82 bill.EUR | 7.09% | 8.46 |
GlobeNewswire
6/18
Pattern To Test Novel AI-Discovered Molecular De Novo Drug for Treatment of Multiple Hard-to-Treat C...
GlobeNewswire
6/16
PetMed Express, Inc. Announces Preliminary Fourth Quarter and FY 2025 Results and Filing of Form 12b...
GlobeNewswire
6/16
Oxbridge / SurancePlus Announces Partnership with Midnight Foundation to Launch Privacy-Enabled Toke...
GlobeNewswire
6/10
U.S. commercial insurance rates continue downward trend, dropping to 5.3% increase
GlobeNewswire
6/4
RadNet, Inc. Acquires See-Mode Technologies for Innovation in AI-Powered Ultrasound Diagnostics
GlobeNewswire
6/4
Check-Cap claims BMO’s Chris Taves Illegally Attacks Israeli NASDAQ-Listed Company During Wartime
GlobeNewswire
5/29
Alzamend Neuro Announces Dosing of First Patient in its Phase II Clinical Trial of AL001 “Lithium in...
GlobeNewswire
5/28
AGS Celebrates Nine Straight Years as a Best and Brightest Company to Work For in the Nation and Atl...
GlobeNewswire
5/27
Pattern Computer Announces Hepatocellular Carcinoma Pattern Identification and Model Creation Study
GlobeNewswire
5/19
Alzamend Neuro Enrolls First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Stud...
GlobeNewswire
5/13
Alzamend Neuro Initiates First Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Plac...
GlobeNewswire
5/12
Oxbridge Re Highlights Growth in Tokenized Reinsurance, Strategic Partnerships, and Reports Q1 2025 ...
GlobeNewswire
5/7
Alzamend Neuro Partners with QMENTA, to Advance AI-Powered Imaging for its Phase II Clinical Trial o...